New Celebrex Label To Warn of Renal Events; Gastrointestinal Benefit Claim Removed
June 13, 2002
WASHINGTON, D.C.- The new FDA-approved warning labels accompanying the arthritis drug Celebrex will continue to educate patients and physicians of the potential risk of gastrointestinal events associated with the anti-inflammatory drug, and include new information for elderly patients concerning gastrointestinal and renal events.
According to the FDA's June 7 press release, the changes were based on the results of the Celecoxib Long-term Arthritis Safety Study (CLASS), which showed Celebrex does not have a safety advantage over other nonsteroidal anti-inflammatory drugs (NSAIDS) regarding the potential risk of gastrointestinal bleeding, ulceration or perforation.
CLASS was a double-blind perspective study consisting of …
UPCOMING CONFERENCES
HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone
June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo
HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates
May 29, 2024 - Salt Lake City, UT
The Grand America Hotel